Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Expense - Debt (2021 - 2022)

Guided Therapeutics' Interest Expense - Debt history spans 2 years, with the latest figure at -$11503.0 for Q2 2022.

  • On a quarterly basis, Interest Expense - Debt fell 200.0% to -$11503.0 in Q2 2022 year-over-year; TTM through Jun 2022 was $28094.0, a N/A change, with the full-year FY2022 number at $39597.0, changed 0.0% from a year prior.
  • Interest Expense - Debt hit -$11503.0 in Q2 2022 for Guided Therapeutics, down from $39597.0 in the prior quarter.
  • Over the last five years, Interest Expense - Debt for GTHP hit a ceiling of $39597.0 in Q1 2022 and a floor of -$11503.0 in Q2 2022.